Updated phase 2 results from the AMETHYST study showed continued improvements in skin disease activity through 52 weeks, with more than one-quarter of patients achieving clear or almost clear skin.
News|Articles|April 30, 2024
A Simple Financing Solution for Medical Aesthetic Practices
The CareCredit healthcare credit card helps improve the payment experience for your patients, while supporting your business goals. By enrolling with CareCredit, you can help reduce cost concerns with our simple, budget friendly financing options and help deliver a positive experience to patients.
Download the fact sheet today to find answers to the most frequently asked questions about CareCredit:
- What is CareCredit?
- How does CareCredit work for patients?
- How does CareCredit work from my practice?
Complete the form below to download the fact sheet.
Sponsored by
Related to this article
Christophe Piketty, MD, PhD, discussed 3-year findings from the ARCADIA long-term extension study and the implications of targeting IL-31 in atopic dermatitis.
In TRANQUILLO 2, 21.86% of patients taking ritlecitinib 100 mg achieved F-VASI75 at week 52 vs 2.40% with placebo, according to data presented at EADV 2026.
At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.
Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.